收费全文 | 343篇 |
免费 | 8篇 |
财政金融 | 87篇 |
工业经济 | 18篇 |
计划管理 | 45篇 |
经济学 | 77篇 |
综合类 | 3篇 |
运输经济 | 3篇 |
旅游经济 | 5篇 |
贸易经济 | 60篇 |
农业经济 | 23篇 |
经济概况 | 29篇 |
邮电经济 | 1篇 |
2023年 | 2篇 |
2022年 | 1篇 |
2021年 | 2篇 |
2020年 | 4篇 |
2019年 | 7篇 |
2018年 | 14篇 |
2017年 | 6篇 |
2016年 | 6篇 |
2015年 | 7篇 |
2014年 | 12篇 |
2013年 | 51篇 |
2012年 | 17篇 |
2011年 | 17篇 |
2010年 | 17篇 |
2009年 | 15篇 |
2008年 | 19篇 |
2007年 | 18篇 |
2006年 | 7篇 |
2005年 | 12篇 |
2004年 | 9篇 |
2003年 | 8篇 |
2002年 | 12篇 |
2001年 | 6篇 |
2000年 | 5篇 |
1999年 | 9篇 |
1998年 | 11篇 |
1997年 | 13篇 |
1996年 | 3篇 |
1995年 | 3篇 |
1994年 | 1篇 |
1993年 | 3篇 |
1992年 | 2篇 |
1991年 | 3篇 |
1990年 | 1篇 |
1989年 | 1篇 |
1988年 | 2篇 |
1986年 | 5篇 |
1985年 | 2篇 |
1984年 | 2篇 |
1983年 | 5篇 |
1982年 | 3篇 |
1980年 | 1篇 |
1979年 | 3篇 |
1978年 | 1篇 |
1977年 | 1篇 |
1973年 | 1篇 |
1961年 | 1篇 |
Methods: The search strategy was designed to identify peer-reviewed cost-effectiveness evaluations of non-surgical, pharmaceutical therapies for neuropathic pain published since January 2000, accessing five key databases. All identified publications were reviewed and screened according to pre-defined eligibility criteria. Data extraction was designed to reflect key data challenges and approaches to modeling in neuropathic pain and based on published guidelines.
Results: The search strategy identified 20 cost-effectiveness analyses meeting the inclusion criteria, of which 14 had original model structures. Cost-effectiveness modeling in neuropathic pain is established and increasing across multiple jurisdictions; however, amongst these studies, there is substantial variation in modeling approach, and there are common limitations. Capturing the effect of treatments upon health outcomes, particularly health-related quality-of-life, is challenging, and the health effects of multiple lines of ineffective treatment, common for patients with neuropathic pain, have not been consistently or robustly modeled.
Conclusions: To improve future economic modeling in neuropathic pain, further research is suggested into the effect of multiple lines of treatment and treatment failure upon patient outcomes and subsequent treatment effectiveness; the impact of treatment-emergent adverse events upon patient outcomes; and consistent and appropriate pain measures to inform models. The authors further encourage transparent reporting of inputs used to inform cost-effectiveness models, with robust, comprehensive and clear uncertainty analysis and, where feasible, open-source modeling is encouraged. 相似文献